Publications by authors named "Patrick Round"

Claim this Profile
A
A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.
S R Shunmugam, Conn Sugihara, Nick Freemantle, Patrick Round, Steve Furniss

J Interv Card Electrophysiol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough.
Maria G Belvisi, Mark A Birrell, Michael A Wortley, Sarah A Maher, Imran Satia, Patrick Round

Am J Respir Crit Care Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
Julian C van Capelleveen, John J P Kastelein, Aeilko H Zwinderman, Sander J H van Deventer, Heidi L Collins, Patrick Round

J Clin Lipidol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.
John Ford, James Milnes, Said El Haou, Erich Wettwer, Simone Loose, Patrick Round

Heart Rhythm· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
G Kees Hovingh, John J P Kastelein, Sander J H van Deventer, Patrick Round, John Ford

Lancet· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
John Ford, Matt Lawson, David Fowler, Nobuko Maruyama, Seiji Mito, Patrick Round

Br J Clin Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of continuous ECG for improvements in assessing the standing response as a positive control for QT prolongation.
Anthony A Fossa, Meijian Zhou, Nuala Brennan, Patrick Round, John Ford

Ann Noninvasive Electrocardiol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects.
Patrick Round, Anthony Priestley, Jan Robinson

Br J Clin Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis